Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PRGO with free AI briefings, catalyst countdowns, and dilution alerts.

PRGO · PERRIGO Co plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$436.6M Cash on Hand
CF+ Cash Runway
Follow PRGO by email Get an email when PRGO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PRGO, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dextromethorphan Common Cold Phase 4 · NCT01257542 Terminated
Vivomixx Breast Cancer Phase 1/2 · NCT03518268 Unknown

Also used in these trials (approved or third-party drugs, not PRGO's own candidates): Pseudoephedrine Hydrochloride, Famotidine, Ibuprofen, Naproxen.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PRGO holds $436.6M in cash and short-term investments (as of Sep 26, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRGO files for a raise →

👥 Who Owns PRGO

Insiders 0.4% Institutions (454 holders) 99.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 20,988,733 15.12% 2026-06-30
Vanguard Portfolio Management Institution (13G, 5%+) 8,254,465 5.95% 2026-03-31
Neuberger Berman Group LLC Institution (13G, 5%+) 7,535,309 5.43% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 7,260,072 5.23% 2026-03-31
Patrick Lockwood-Taylor
Former CEO and director · +50,458 options
Insider 123,170 0.09% 2026-06-05
Eduardo Guarita Bezerra
EVP & Chief Financial Officer · +141,376 options
Insider 84,700 0.06% 2026-07-08
Geoffrey M. Parker
Director
Insider 77,127 0.06% 2026-09-11
Robert Willis
EVP & CHRO · +60,085 options
Insider 50,568 0.04% 2026-07-08
Bradley A Alford
Director · +2,059 options
Insider 46,121 0.03% 2026-09-11
Donal O'Connor
Director
Insider 35,633 0.03% 2026-05-13
Albert Manzone
Interim President and CEO, Director · +235,627 options
Insider 16,353 0.01% 2026-07-08
Roberto Khoury
EVP and President of CSCI · +113,101 options
Insider 14,113 0.01% 2026-07-08

Share count 138,801,872 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PRGO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRGO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.